Phase I trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer. - Rudin,C.M.; Holmlund,J.; Fleming,G.F.; Mani,S.; Stadler,W.M.; Schumm,P.; Monia,B.P.; Johnston,J.F. (Clin Cancer Res, 2001)